FEMYNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

FEMASYS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$1.63−0.02 (-1.21%)

Close on Oct 19, 2026

Market cap: $5.47M
P/E (TTM): –
Dividend yield: –

FEMASYS INC income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	2.29	1.63	1.07	1.21	1.18	1.04
Cost of Revenue	0.87	0.54	0.38	0.44	0.37	0.31
Gross Profit	1.42	1.08	0.69	0.76	0.81	0.73
Research & Development	7.58	8.22	7.21	5.81	4.08	4.13
Selling, General & Admin	11	10	7.51	5.99	4.47	2.85
Selling & Marketing	4.44	4.03	0.65	0.56	0.21	0.31
General & Administrative	6.65	6.33	6.86	5.43	4.26	2.54
Advertising Expenses	0.26	0.36	0.02	0.04	0.03	0.00
Operating Expenses	19	19	15	12	9.15	7.66
Operating Income	-18	-18	-15	-12	-8.34	-6.93
Interest Expense	1.89	1.60	0.17	0.01	0.02	0.01
Interest & Investment Income	0.10	0.58	0.43	–	–	–
Other Non-Operating Income	-1.04	-1.02	0.27	0.21	0.80	0.02
Asset Impairment Charges	0	0	0	0	0	–
Gain (Loss) on Sale of Assets	-0.06	0.00	-0.05	0.00	0.00	0
Pretax Income	-19	-19	-14	-11	-7.53	-6.91
Income Tax Expense	0.00	0.01	0.00	0.01	0.00	0.00
Net Income	-19	-19	-14	-11	-7.54	-6.91
Net Income to Common	-19	-19	-14	-11	-7.54	-6.91
EPS (Basic)(per share)	-9.40	-17.00	-18.60	-19.20	-22.40	-144.00
EPS (Diluted)(per share)	-9.40	-17.00	-18.60	-19.20	-22.40	-144.00
Shares Outstanding (Basic, Weighted)(shares)	1.98	1.11	0.77	0.59	0.34	0.05
Shares Outstanding (Diluted, Weighted)(shares)	1.98	1.11	0.77	0.59	0.34	0.05
EBITDA	-17	-17	-14	-11	-7.75	-6.25

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 60.9%
Operating margin: -763.9%
Net margin: -511.8%
Return on equity, FY2025: -455.8%

Financial strength

Current ratio: 2.14
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 37.1%

Valuation

P/E ratio: –
Price to sales: 2.38
Price to book: 1.36
Dividend yield: –